Skip to main navigation
Top Links - Left
BioNTech.com
Newsroom
Investors
Healthcare Professionals
English
Language switcher (Content)
English
German
Top Links - Right
Connect
Main Navigation
BioNTech.com
News
Events & Presentations
Financials
Financials
SEC Filings
Annual Reports
Quarterly Reports
Financial Calendar
Corporate Governance
Corporate Governance
Overview
Transparency
ESG
Stock Info
Stock Info
Stock Quote & Chart
Analyst Coverage
Shareholder Fraud Warning
Share Repurchase Program
Dividend Information
Investor FAQs
Annual General Meeting
Annual General Meeting
Annual General Meeting 2024
Annual General Meeting Archive
Contact Us
Newsroom
Investors
Healthcare Professionals
Breadcrumb
Investors
Search
Search
Filter by content type
Asset
(137)
News
(86)
SEC filing
(47)
Event
(31)
Filter by content year
(-)
2023
(301)
Filter by form group
Filter by category
Filter by category
Search
News
BioNTech erreicht Meilenstein in der Errichtung einer Produktionsstätte für mRNA-basierte Impfstoffe in Ruanda
News
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
Event
JP Morgan Annual Healthcare Conference
Event
JP Morgan Annual Healthcare Conference
Asset
20230609 BioNTech Weekly Buyback Report DE
20230609 BioNTech Weekly Buyback Report DE
546.1 KB
Asset
Safety, Health, Environment and Energy Policy Statement
Safety, Health, Environment and Energy Policy Statement
145 KB
News
Pfizer und BioNTech starten Einreichungsprozess zur Zulassung eines an Omikron XBB.1.5 angepassten monovalenten COVID-19-Impfstoffs bei der Europäischen Arzneimittel-Agentur
News
Pfizer and BioNTech Initiate Application to European Medicines Agency for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine
SEC Filings
Form 6-K
News
Pfizer and BioNTech Submit Applications to U.S. FDA for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine
Pagination
Page 1
Next page
››